Sandwich ELISA, HRP-labelled antibody
Serum, Plasma-EDTA, Plasma-Heparin, Amniotic fluid, Cell culture supernatant
100 µl (1:20 prediluted)
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store kit reagents between 2–8°C except controls. Store lyophilized controls at –20°C.
Limit of Detection
CV = 1.9%
CV = 5.8%
The human HER-2 (p158 HER-2, c-erbB-2, neu) gene encodes a putative transmembrane growth
factor receptor (p185 protein) that is closely related to the epidermal growth factor receptor
protein. The HER-2 gene product is a 185 kDa glycoprotein that contains an extracellular
ligand-binding domain and intracellular tyrosine kinase activity. HER-2 protein staining is
observed only in low levels in epithelial cells of most organs in normal human tissues and at
slightly higher levels in fetal tissues.
Both HER-2 oncogene amplification and oncoprotein overexpression have been analyzed for
potential utility in diagnostic and prognostic tests for: breast, ovarian, gastric, lung; and other
cancers. In these malignancies the HER-2 oncoprotein overexpression is correlated with
a poor prognosis.
In 15-40 % of primary breast cancers, amplification of the HER-2 oncogen is found which is
highly correlated with overexpression of the encoded 185 kDa protein and seems to play
a major role especially during the initiation of ductal carcinomas. HER-2 protein overexpression
is described as independent prognostic factor with greater predictive power than most
of the currently used prognostic tools - especially in axillary lymph-node-positive breast cancer
Studies analyzing small series of patients have suggested a prognostic value for HER-2
oncoprotein expression in axillary node negative (ANN) patients. An association between
oncoprotein expression and decreased overall survival among ANN patients with good nuclear
grade tumors has been demonstrated. In addition it has been reported that in low risk patients
(estrogen receptor positive, small tumors), HER-2 protein expression was associated with early
recurrence. Data demonstrate the large body of evidence implicating HER-2 oncoprotein
in the biology and prognosis of breast carcinoma.